April 22nd 2024
Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Gemcitabine/Cisplatin/Nivolumab as Bladder Sparing Therapy in MIBC
October 26th 2023A phase 2 study of neoadjuvant gemcitabine, cisplatin, plus nivolumab met its co-primary end point with a positive predictive value of clinical complete response of 0.97 among patients with muscle-invasive bladder cancer.
Read More
Survival Improved With Nivolumab Plus Chemo in Urothelial Carcinoma
October 22nd 2023The addition of nivolumab to frontline standard of care gemcitabine-cisplatin, followed by nivolumab maintenance therapy, led to statistically significant and clinically meaningful improvements in survival compared with gemcitabine-cisplatin alone in patients with unresectable or metastatic urothelial carcinoma.
Read More
Nadofaragene Firadenovec-vncg Dosed in First Commercial Patient With NMIBC
September 14th 2023Nadofaragene firadenovec-vncg received FDA approval for patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer in 2022, and is now being evaluated further in the ABLE-41 trial.
Read More
Study Design and Inclusion Criteria of the EV-103 Study in Advanced Urothelial Carcinoma
July 31st 2023Jonathan E. Rosenberg, MD, explains the study design and patient inclusion criteria of the phase 2 EV-103 study investigating combination enfortumab vedotin plus pembrolizumab for the treatment of patients with metastatic or locally advanced urothelial carcinoma.
Watch
Results of the EV-103 Study in Patients With Advanced Urothelial Carcinoma
July 31st 2023Jonathan E. Rosenberg, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, in reviewing the results of the EV-103 study in patients with metastatic or locally advanced urothelial carcinoma.
Watch
Choosing an Appropriate Treatment Regimen for Patients With Advanced Urothelial Carcinoma
July 31st 2023Experts explain how they would choose between combination therapy regimens for patients with metastatic or locally advanced urothelial carcinoma if the choice of treatment was not influenced by low supply availability.
Watch